» Articles » PMID: 31570516

Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis

Overview
Journal Oncologist
Specialty Oncology
Date 2019 Oct 2
PMID 31570516
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Polypharmacy (PP) and potentially inappropriate medications (PIM) are highly prevalent in older adults with cancer. This study systematically reviews the associations of PP and/or PIM with outcomes and, through a meta-analysis, obtains estimates of postoperative outcomes associated with PP in this population.

Materials And Methods: We searched PubMed, Embase, Web of Science, and Cochrane Register of Clinical Trials using standardized terms for concepts of PP, PIM, and cancer. Eligible studies included cohort studies, cross-sectional studies, meta-analyses, and clinical trials which examined outcomes associated with PP and/or PIM and included older adults with cancer. A random effects model included studies in which definitions of PP were consistent to examine the association of PP with postoperative complications.

Results: Forty-seven articles met the inclusion criteria. PP was defined as five or more medications in 57% of the studies. Commonly examined outcomes included chemotherapy toxicities, postoperative complications, functional decline, hospitalization, and overall survival. PP was associated with chemotherapy toxicities (4/9 studies), falls (3/3 studies), functional decline (3/3 studies), and overall survival (2/11 studies). A meta-analysis of four studies indicated an association between PP (≥5 medications) and postoperative complications (overall odds ratio, 1.3; 95% confidence interval [1.3-2.8]). PIM was associated with adverse outcomes in 3 of 11 studies.

Conclusion: PP is associated with postoperative complications, chemotherapy toxicities, and physical and functional decline. Only three studies showed an association between PIM and outcomes. However, because of inconsistent definitions, heterogeneous populations, and variable study designs, these associations should be further investigated in prospective studies.

Implications For Practice: Polypharmacy and potentially inappropriate medications (PIM) are prevalent in older adults with cancer. This systematic review summarizes the associations of polypharmacy and PIM with health outcomes in older patients with cancer. Polypharmacy and PIM have been associated with postoperative complications, frailty, falls, medication nonadherence, chemotherapy toxicity, and mortality. These findings emphasize the prognostic importance of careful medication review and identification of PIM by oncology teams. They also underscore the need to develop and test interventions to address polypharmacy and PIM in older patients with cancer, with the goal of improving outcomes in these patients.

Citing Articles

Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study.

Brandstetter L, Grau A, Heuschmann P, Muller-Reiter M, Salmen J, Stork S BMC Cancer. 2025; 25(1):125.

PMID: 39844089 PMC: 11756166. DOI: 10.1186/s12885-025-13548-8.


Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada.

Campeau Calfat A, Turner J, Simard M, Boiteau V, Sirois C Ther Adv Drug Saf. 2024; 15:20420986241309882.

PMID: 39737141 PMC: 11683794. DOI: 10.1177/20420986241309882.


Transoral Laser Microsurgery and Transoral Robotic Surgery in Aging Patients: A State-of-The-Art Review.

Lechien J Clin Interv Aging. 2024; 19:2121-2132.

PMID: 39691799 PMC: 11651065. DOI: 10.2147/CIA.S475037.


Optimizing Care Across the Continuum for Older Adults with Lung Cancer: A Review.

Thompson L, Florissi C, Yoon J, Singh A, Saraf A Cancers (Basel). 2024; 16(22).

PMID: 39594755 PMC: 11593030. DOI: 10.3390/cancers16223800.


Polypharmacy and potentially inappropriate medicine use in older adults with cancer: a multicenter cross-sectional study in Northwest Ethiopia oncologic centers.

Wondm S, Moges T, Dagnew S, Dagnew F, Zeleke T, Abebe R J Pharm Policy Pract. 2024; 17(1):2397797.

PMID: 39359864 PMC: 11445903. DOI: 10.1080/20523211.2024.2397797.


References
1.
Hamaker M, Seynaeve C, Wymenga A, van Tinteren H, Nortier J, Maartense E . Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. Breast. 2013; 23(1):81-7. DOI: 10.1016/j.breast.2013.11.004. View

2.
Karuturi M, Holmes H, Lei X, Johnson M, Barcenas C, Cantor S . Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol. 2019; 10(5):705-708. PMC: 6699920. DOI: 10.1016/j.jgo.2019.01.024. View

3.
Elliot K, Tooze J, Geller R, Powell B, Pardee T, Ritchie E . The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014; 38(10):1184-90. PMC: 4182134. DOI: 10.1016/j.leukres.2014.06.018. View

4.
Park J, Roh J, Lee S, Kim S, Choi S, Nam S . Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. J Cancer Res Clin Oncol. 2016; 142(5):1031-40. DOI: 10.1007/s00432-015-2108-x. View

5.
Todd A, Holmes H . Recommendations to support deprescribing medications late in life. Int J Clin Pharm. 2015; 37(5):678-81. PMC: 4682203. DOI: 10.1007/s11096-015-0148-6. View